Saturday, April 13, 2013

B&E This Fortnight

INTERNATIONALBUSINESS, ECONOMY & FINANCE
END OF AN ERA!

August 25, 2011, witnessed the end of one of the most extraordinary careers in business history. Steve Jobs, the ‘Minister of Magic’ at Apple Inc. finally stepped down as CEO of the tech giant citing health concerns and his inability to run the company on a day-to-day basis. Surprisingly, the market did not panic and the company’s stock performed better than the NASDAQ and Dow index – an indication that Jobs had succeeded in crafting a brilliant succession plan. Steve Jobs has been one of the most iconic CEOs in business history and his relentless pursuit for perfection and innovation has earned him a fortune. As of today, Jobs holds Apple shares worth $2.2 billion. Additionally, he is also the largest shareholder in Disney where his shareholding amounts to a staggering $4.4 billion. Tim Cook has been named the new CEO. Although Cook has been responsible for the day-to-day operations of the company in Jobs’ absence, he faces the daunting task of stepping into the historic CEO’s shoes. Ever since Jobs came back to Apple in 1997, the company’s stock price has appreciated by 6,754%. If today, Cook were to replicate the same, the stock would be valued at $25,797 and the m-cap would hover around $23.6 trillion! Nevertheless, Jobs would always be remembered as a maverick who inspired an entire generation of entrepreneurs.

Takeda eyeing india
It seems that the Indian government’s decision to allow 100% foreign direct investment (FDI) in the pharmaceuticals sector will strip India of its generic competitive advantage. Japan’s largest pharmaceuticals company Takeda is planning to acquire one of India’s leading pharma companies. Unlike its rival Daiichi Sankyo, Takeda does not have a formidable presence in the Indian market. The Osaka headquartered Takeda has approached Cipla (India’s second largest drug company) and Lupin (fifth largest by market share) to lead their endeavour of making a denting mark in the Indian drug market. For Lupin, the talks have progressed beyond the initial stage wherein Takeda plans to buy its domestic formulations business as well as its research facilities. However, Lupin is precarious over selling off its research facilities and expects a price valued at 17 times Lupin’s revenue, which stood at $1.5 billion in FY2011. On the other hand, Cipla has denied any such developments. Last year, US based Abbott bought Piramal Healthcare’s formulation business for over Rs.170 billion, which made it the country’s biggest pharma player by market share. Similarly in 2009, Daiichi Sankyo purchased Ranbaxy for $3.5-4 billion to become India’s largest pharma player by revenue.


Source : IIPM Editorial, 2012.
An Initiative of IIPM, Malay Chaudhuri
 
For More IIPM Info, Visit below mentioned IIPM articles
 
Posted by at
Labels: , , , , , , , , , ,